Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PDSB
stocks logo

PDSB

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.200
-4.76%
--
--
-0.180
-14.29%
--
--
-0.180
-14.29%
Estimates Revision
The market is revising No Change the revenue expectations for PDS Biotechnology Corporation (PDSB) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -25.49%.
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-25.49%
In Past 3 Month
Wall Street analysts forecast PDSB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PDSB is 9.00 USD with a low forecast of 3.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast PDSB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PDSB is 9.00 USD with a low forecast of 3.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.894
sliders
Low
3.00
Averages
9.00
High
15.00
Current: 0.894
sliders
Low
3.00
Averages
9.00
High
15.00
B. Riley
Buy
downgrade
$5 -> $3
2025-11-25
Reason
B. Riley
Price Target
$5 -> $3
2025-11-25
downgrade
Buy
Reason
B. Riley lowered the firm's price target on PDS Biotechnology to $3 from $5 and keeps a Buy rating on the shares. The shares remain attractively valued with near-zero EV that fails to reflect impact of this recent strategic pivot on enrollment size, efficacy endpoint durations and an enriched p16+ve population with limited competing trials, the analyst tells investors in a research note.
H.C. Wainwright
Buy
maintain
$13 -> $15
2025-11-13
Reason
H.C. Wainwright
Price Target
$13 -> $15
2025-11-13
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on PDS Biotechnology to $15 from $13 and keeps a Buy rating on the shares. The firm is increasing its view of the probability of success for PDS0101 in head and neck cancer to 65% from 40% following the most recent median overall survival data from the VERSATILE-002 study, the analyst tells investors.
B. Riley
Buy
downgrade
$7 -> $5
2025-04-25
Reason
B. Riley
Price Target
$7 -> $5
2025-04-25
downgrade
Buy
Reason
B. Riley lowered the firm's price target on PDS Biotechnology to $5 from $7 and keeps a Buy rating on the shares. The firm cites PDS01 f antibody drug conjugate triplet revenue contribution push out given the company's heightened focus on securing Versamune HPV doublet path to market for the target cut.
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Maintains
$21 → $13
2025-03-27
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$21 → $13
2025-03-27
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$21
2025-03-13
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$21
2025-03-13
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$21
2025-03-07
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$21
2025-03-07
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for PDS Biotechnology Corp (PDSB.O) is -1.22, compared to its 5-year average forward P/E of -4.82. For a more detailed relative valuation and DCF analysis to assess PDS Biotechnology Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.82
Current PE
-1.22
Overvalued PE
-0.51
Undervalued PE
-9.14

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.52
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.26
Undervalued EV/EBITDA
-7.30

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
86.10
Current PS
0.00
Overvalued PS
462.02
Undervalued PS
-289.83
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

PDSB News & Events

Events Timeline

(ET)
2025-12-02
08:40:00
PDS Biotechnology Secures FDA Meeting to Discuss Accelerated Approval for PDS0101
select
2025-11-13 (ET)
2025-11-13
07:34:39
PDS Biotechnology announces Q3 earnings per share of 19 cents, below consensus estimate of 20 cents.
select
2025-11-11 (ET)
2025-11-11
15:34:26
PDS Biotechnology reveals registered direct offering of up to $11.1 million
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-02Newsfilter
PDS Biotechnology Secures FDA Meeting to Discuss Accelerated Approval for PDS0101
  • FDA Meeting Approval: PDS Biotechnology's request for a Type C meeting with the FDA has been accepted, scheduled for this month to discuss the accelerated approval pathway for PDS0101 in HPV16-positive recurrent head and neck cancer, marking a significant advancement in the company's cancer immunotherapy efforts.
  • Clinical Trial Results: The final results from the VERSATILE-002 trial demonstrated promising median overall survival and durable progression-free survival, providing data support for the accelerated approval of PDS0101, potentially shortening the regulatory approval timeline.
  • Trial Design Change: The company plans to amend the VERSATILE-003 Phase 3 trial to change the progression-free survival endpoint to a surrogate primary endpoint that can be evaluated earlier, enhancing statistical power and laying the groundwork for accelerated approval, thereby increasing market competitiveness.
  • Strategic Outlook: PDS Biotechnology's CEO stated that the positive progression-free survival data offers a crucial opportunity to shorten the duration to a primary endpoint, which is expected to expedite treatment availability, meet patient needs, and enhance the company's position in the cancer treatment market.
[object Object]
Preview
4.5
11-20TipRanks
VTI ETF Daily Update - November 20, 2025

  • VTI Overview: The Vanguard Total Stock Market ETF (VTI) offers broad exposure to the U.S. equity market with a low expense ratio of 0.03%, making it a cost-effective investment option.

  • Recent Performance: VTI has experienced a 2.74% decline over the past week but is up 13.0% year-to-date, with a recent gain of 0.33% and an additional 1.14% in pre-market trading.

  • Top Holdings and Analyst Consensus: VTI's top holdings include Nvidia, Microsoft, and Apple, with a Moderate Buy consensus from analysts and a price target suggesting a 19.5% upside.

  • Potential Upside and Downside: The ETF's holdings with the highest upside potential include Jupiter Neurosciences and Cibus, while those with the greatest downside risk include LXP Industrial Trust and iHeartMedia.

[object Object]
Preview
2.0
10-06TipRanks
VTI ETF Update, October 6, 2025

  • VTI Stock Performance: The Vanguard Total Stock Market ETF (VTI) has increased by 0.78% over the past week and 14.92% year-to-date, with a Moderate Buy consensus from analysts and a price target suggesting an 11.7% upside.

  • Holdings Analysis: VTI's top five holdings with the highest upside potential include BioAtla and Cibus, while those with the greatest downside risk include Wolfspeed and Opendoor Technologies; the ETF's Smart Score indicates it is likely to perform in line with the market.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is PDS Biotechnology Corp (PDSB) stock price today?

The current price of PDSB is 0.8941 USD — it has increased 5.05 % in the last trading day.

arrow icon

What is PDS Biotechnology Corp (PDSB)'s business?

PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents.

arrow icon

What is the price predicton of PDSB Stock?

Wall Street analysts forecast PDSB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PDSB is 9.00 USD with a low forecast of 3.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is PDS Biotechnology Corp (PDSB)'s revenue for the last quarter?

PDS Biotechnology Corp revenue for the last quarter amounts to -8.14M USD, decreased -20.03 % YoY.

arrow icon

What is PDS Biotechnology Corp (PDSB)'s earnings per share (EPS) for the last quarter?

PDS Biotechnology Corp. EPS for the last quarter amounts to -5916048.00 USD, decreased -26.05 % YoY.

arrow icon

What changes have occurred in the market's expectations for PDS Biotechnology Corp (PDSB)'s fundamentals?

The market is revising No Change the revenue expectations for PDS Biotechnology Corporation (PDSB) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -25.49%.
arrow icon

How many employees does PDS Biotechnology Corp (PDSB). have?

PDS Biotechnology Corp (PDSB) has 24 emplpoyees as of December 05 2025.

arrow icon

What is PDS Biotechnology Corp (PDSB) market cap?

Today PDSB has the market capitalization of 47.23M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free